AstraZeneca (AZN) announced Monday morning that it agreed to acquire Ardea Biosciences Inc. (RDEA) for $32 per share, or approximately $1.26 billion.
Ardea Biosciences gapped open dramatically higher Monday, but traded in a narrow range throughout the session. Shares finished up by 10.78 at $31.62 on the highest volume of the year. The stock surged to a new high for the year.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org